Oral oncology最新文献

{"title":"Insights on the pilot randomized controlled trial of LEF-SM program for HNC survivors: addressing HPV stratification, adherence measurement, and IMB component dissection","authors":"Zhichao Feng","doi":"10.1016/j.oraloncology.2025.107748","DOIUrl":"10.1016/j.oraloncology.2025.107748","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"170 ","pages":"Article 107748"},"PeriodicalIF":3.9,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145268934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma","authors":"Min Hee Hong ,&nbsp;Seoyoung Lee ,&nbsp;Chang Gon Kim ,&nbsp;Wonrak Son ,&nbsp;Jin Woo Park ,&nbsp;Sun Och Yoon ,&nbsp;Su-Jin Shin ,&nbsp;Hyun Jun Hong ,&nbsp;Yoon Woo Koh ,&nbsp;Jae-Yol Lim ,&nbsp;Young Min Park ,&nbsp;Chan Woo Wee ,&nbsp;Kyung Hwan Kim ,&nbsp;Chang Geol Lee ,&nbsp;Jun Won Kim ,&nbsp;Jinna Kim ,&nbsp;Pae Sun Suh ,&nbsp;Sung Uk Kuh ,&nbsp;Da Hee Kim ,&nbsp;Nam Suk Sim ,&nbsp;Hye Ryun Kim","doi":"10.1016/j.oraloncology.2025.107745","DOIUrl":"10.1016/j.oraloncology.2025.107745","url":null,"abstract":"<div><h3>Background</h3><div>Neoadjuvant chemotherapy (NACT) is being explored in head and neck squamous cell carcinoma (HNSCC) to improve resectability and long-term survival. This phase II study evaluated the efficacy and safety of paclitaxel-carboplatin as NACT in patients with locally advanced HNSCC.</div></div><div><h3>Methods</h3><div>Patients with stage III–IV oral cavity, hypopharynx, larynx, or HPV-negative oropharyngeal cancer, or stage II–III HPV-positive oropharyngeal cancer received two cycles of paclitaxel (175 mg/m²) and carboplatin (AUC 5) every 3 weeks, followed by surgery. The primary endpoint was major pathologic response (MPR, ≤10 % viable tumor). Secondary endpoints included overall survival (OS), relapse-free survival (RFS), and safety.</div></div><div><h3>Results</h3><div>Of 79 enrolled patients, 72 underwent curative-intent surgery. The MPR rate was achieved in 30.6 % (22/72), including 12.5 % with pathologic complete response (pCR). The highest MPR rate was observed in HPV-positive oropharyngeal cancer (44.7 %). Pathologic downstaging occurred in 55.6 % of patients. Median OS and RFS were not reached; 2-year OS and RFS were 89.2 % and 75.5 %, respectively. MPR was associated with numerically improved OS and RFS. Radiologic and pathologic responses were frequently discordant. Grade ≥3 adverse events occurred in 29.1 % of patients, primarily neutropenia (21.5 %), with a lower incidence observed in the pegylated granulocyte-colony stimulating factor group.</div></div><div><h3>Conclusions</h3><div>Neoadjuvant paclitaxel-carboplatin demonstrated favorable efficacy and manageable toxicity in resectable HNSCC, with MPR and pCR rates comparable to or exceeding historical benchmarks from more intensive regimens. Although the MPR target was not met, observed outcomes compare favorably with historical controls, supporting its use as a chemotherapy backbone in future perioperative combination trials.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"170 ","pages":"Article 107745"},"PeriodicalIF":3.9,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145270152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant chemotherapy combined with anti-PD-1 monoclonal antibody in locally advanced resectable oral squamous cell carcinoma: efficacy evaluation and prediction","authors":"Xiaotong He ,&nbsp;Yi Xu ,&nbsp;Yuqing Ren ,&nbsp;Jiayi Wang ,&nbsp;Youkang Ni ,&nbsp;Yulong Zheng ,&nbsp;Yanli Wang ,&nbsp;Xiaofan Ding ,&nbsp;Yining Li ,&nbsp;Huiyong Zhu","doi":"10.1016/j.oraloncology.2025.107744","DOIUrl":"10.1016/j.oraloncology.2025.107744","url":null,"abstract":"<div><h3>Background</h3><div>Neoadjuvant chemotherapy (NAC) combined with anti-PD-1 antibody therapy is a potential treatment option for resectable oral squamous cell carcinoma (OSCC). Identifying biomarkers to predict therapeutic efficacy remains critical for optimizing this regimen.</div></div><div><h3>Methods</h3><div>Thirty patients with locally advanced, resectable OSCC (T3–T4, N0–N2, M0) who received two cycles of neoadjuvant chemoimmunotherapy (NACI) consisting of paclitaxel (175 mg/m²) and cisplatin (75 mg/m²) plus the anti-PD-1 monoclonal antibody sintilimab (200 mg) were enrolled in this single-arm phase II trial. Twenty-five patients underwent surgical resection and five received nonsurgical therapy. The primary and secondary end points were pathological response and clinical response, respectively. AI-powered nuclear segmentation and classification was applied to pre-treatment biopsy samples to spatially map inflammatory cell infiltration. Transcriptome RNA sequencing (RNA-seq) analysis and IHC were used to identify differentially expressed genes and immune cell subtypes between patients with and without major pathological response (MPR).</div></div><div><h3>Results</h3><div>The MPR rate was 44.0 % among the 25 patients who underwent surgical resection. The objective response rate (ORR) was 53.3 %. The primary tumor location significantly correlated with pathological response (<em>P</em> &lt; 0.05). While AI analysis showed no significant difference in overall inflammatory cell infiltration between groups, immune infiltration analysis of the RNA-seq data revealed significant differences in the proportions of M1- and M2-type macrophages between the MPR and non-MPR groups. CD86 IHC validation across all 12 sequenced patients confirmed significantly elevated M1 infiltration in MPR tumors (13.75 % vs. 4.5 % CD86⁺ cells, <em>P</em> &lt; 0.001), directly linking M1 polarization to therapeutic sensitivity to PD-1 inhibition.</div></div><div><h3>Conclusions</h3><div>NAC combined with anti-PD-1 antibody therapy demonstrates clinically meaningful efficacy in OSCC, accompanied by a manageable toxicity profile. M1 macrophage infiltration, validated by both RNA-seq and IHC, emerges as a novel predictive biomarker for pathological response, providing mechanistic insight into PD-1 blockade efficacy within the tumor microenvironment.</div></div><div><h3>Trial registration</h3><div>Chinese clinical trial registry, ChiCTR2400091891.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"170 ","pages":"Article 107744"},"PeriodicalIF":3.9,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145270149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma","authors":"Thangapandi Marudhupandi","doi":"10.1016/j.oraloncology.2025.107746","DOIUrl":"10.1016/j.oraloncology.2025.107746","url":null,"abstract":"<div><div>A recent study by Tang et al. explores the predictive role of circulating tumor tissue-modified HPV DNA (TTMV-HPV DNA) kinetics during induction therapy in oropharyngeal squamous cell carcinoma (OPSCC). It demonstrates that liquid biopsy biomarkers can effectively evaluate treatment response. By tracking real-time fluctuations in HPV DNA, the study offers a non-invasive method to predict therapy outcomes and enhance patient selection for organ-preserving strategies. This highlights the increasing importance of circulating biomarkers in advancing personalized cancer treatment. The following steps should involve validating these findings across multiple centers, integrating them with imaging and molecular data, and conducting prospective trials to confirm their clinical value. Overall, this work represents a significant advancement toward tailored, biomarker-driven therapy for HPV-related OPSCC.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"170 ","pages":"Article 107746"},"PeriodicalIF":3.9,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145268933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Donor-site morbidity in sarcopenic patients: An overlooked pathway to complications","authors":"Muhammad Mohid Haroon","doi":"10.1016/j.oraloncology.2025.107747","DOIUrl":"10.1016/j.oraloncology.2025.107747","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"170 ","pages":"Article 107747"},"PeriodicalIF":3.9,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145268716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on \"Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma\".","authors":"Gnanaprakash Jeyaraj","doi":"10.1016/j.oraloncology.2025.107741","DOIUrl":"https://doi.org/10.1016/j.oraloncology.2025.107741","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":" ","pages":"107741"},"PeriodicalIF":3.9,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145275453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: “The role of adjuvant radiotherapy in relation to tumor size for bone-invasive pT4aN0 oral squamous cell carcinoma-A retrospective observational matched cohort study”","authors":"Mengting Zhang","doi":"10.1016/j.oraloncology.2025.107727","DOIUrl":"10.1016/j.oraloncology.2025.107727","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"170 ","pages":"Article 107727"},"PeriodicalIF":3.9,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145268715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: the lymph node ratio is a prognostic factor for survival in laryngeal and hypopharyngeal squamous cell carcinoma","authors":"Yanan Duan","doi":"10.1016/j.oraloncology.2025.107702","DOIUrl":"10.1016/j.oraloncology.2025.107702","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"170 ","pages":"Article 107702"},"PeriodicalIF":3.9,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145258771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: The role of adjuvant radiotherapy in relation to tumor size for bone-invasive pT4aN0 oral squamous cell carcinoma – A retrospective observational matched cohort study","authors":"Shenghao Lin ,&nbsp;Leyin Zhang ,&nbsp;Leitao Sun","doi":"10.1016/j.oraloncology.2025.107732","DOIUrl":"10.1016/j.oraloncology.2025.107732","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"170 ","pages":"Article 107732"},"PeriodicalIF":3.9,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: “Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: A pilot randomized controlled trial”","authors":"Yuanqi Li ,&nbsp;Shijun Tong ,&nbsp;Jinbao Tian ,&nbsp;Xing You ,&nbsp;Yunruo Chen ,&nbsp;Fangyuan Du","doi":"10.1016/j.oraloncology.2025.107729","DOIUrl":"10.1016/j.oraloncology.2025.107729","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"170 ","pages":"Article 107729"},"PeriodicalIF":3.9,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}